(Q45866665)

English

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

scientific article published in January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

Alzheimer's disease

1 reference

based on heuristic

inferred from title

author name string

X A Alvarez

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

R Cacabelos

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

C Sampedro

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

M Aleixandre

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

C Linares

5

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

E Granizo

6

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

E Doppler

7

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

H Moessler

8

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

publication date

1 January 2011

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

European Journal of Neurology

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

18

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

59-68

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

Pharmacotherapy of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Amyloid-beta immunisation for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Treatment of moderate to severe Alzheimer's disease: rationale and trial design

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Pathological verification of ischemic score in differentiation of dementias.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Disease stage in Alzheimer disease and treatment effects of rivastigmine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Depression, comorbidities and the TNF-α system

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03092.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2010.03092.X

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/20500802

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45866665&oldid=2087654333"